DelveInsight Releases Pulmonary Arterial Hypertension Market Report

DelveInsight has released a new report offering detailed market insights into Pulmonary Arterial Hypertension (PAH). The 183-page analysis, titled 'Pulmonary Arterial Hypertension (PAH)–Market Insights, Epidemiology, and Market Forecast—2030,' was published in 2021 and provides a comprehensive overview of the disease's epidemiology and market trends across key regions.

The report focuses on the United States, Japan, and EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), covering the study period from 2018 to 2030. It analyzes current treatment practices, emerging drug developments, and the market share of individual therapies. The report also forecasts the market size for PAH symptoms from 2018 to 2030, examining market drivers, barriers, and unmet medical needs.

Pulmonary Arterial Hypertension is a progressive disease affecting the lung's vascular system, particularly the small pulmonary arterioles. It is characterized by elevated pulmonary artery pressure and narrowing of the blood vessels. The condition can stem from various causes, including idiopathic forms, genetic factors, or associations with other conditions. Symptoms commonly include progressive dyspnea on exertion, fatigue, and exhaustion, which can lead to diagnostic delays.

The delays in diagnosis highlight the need for early identification and accurate classification. This report aims to provide insights to understand market potential and identify new opportunities for the development and marketing of PAH treatments.